Ad­comm backs use of min­i­mal resid­ual dis­ease in mul­ti­ple myelo­ma ac­cel­er­at­ed ap­provals

A new on­col­o­gy drug end­point, based on what’s known as min­i­mal resid­ual dis­ease, gained the back­ing of FDA ad­vi­sors, po­ten­tial­ly open­ing the door to new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.